The latest price target for CytomX Therapeutics (NASDAQ:CTMX) was reported by Piper Sandler on March 23, 2026. The analyst firm set a price target for $12.00 expecting CTMX to rise to within 12 months (a possible 172.73% upside). 22 analyst firms have reported ratings in the last year.

The latest analyst rating for CytomX Therapeutics (NASDAQ:CTMX) was provided by Piper Sandler, and CytomX Therapeutics maintained their overweight rating.

The last upgrade for CytomX Therapeutics Inc happened on March 16, 2026 when JP Morgan raised their price target to $12. JP Morgan previously had a neutral for CytomX Therapeutics Inc.

There is no last downgrade for CytomX Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CytomX Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CytomX Therapeutics was filed on March 23, 2026 so you should expect the next rating to be made available sometime around March 23, 2027.

While ratings are subjective and will change, the latest CytomX Therapeutics (CTMX) rating was a maintained with a price target of $10.00 to $12.00. The current price CytomX Therapeutics (CTMX) is trading at is $4.40, which is out of the analyst’s predicted range.